CYGS Initiates Antisense Animal Studies.HOUSTON--(BUSINESS WIRE)--Oct. 23, 1998--Cryogenic Solutions Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CYGS) announced it has recently entered into an agreement with the Southwest Foundation for Biomedical Research Southwest Foundation for Biomedical Research (SFBR) is a large private research institute located in San Antonio Texas. With 400 staff and a 397 acre campus, SFBR is "one of the world's leading independent biomedical research institutions. to undertake animal testing of its proprietary ssDNA expression vector expression vector n. A vector, such as a plasmid, yeast, or animal virus genome, used to introduce foreign genetic material into a host cell in order to replicate and amplify the foreign DNA sequences as a recombinant molecule. . The tests will be conducted by Dr. Jason T. Kimata and supervised by Dr. Jean L. Patterson, chairman of the Department of Virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression and Immunology. The animal studies are intended to demonstrate the ability of the ssDNA expression vector to synthesize pharmacologically significant titers of sequence specific, antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). competent oligodeoxyribonucleotides intracellularly in an animal model. "We expect to show in a primate that we have overcome the oligo delivery barrier and with controllable expression of ssDNA," said company president, Laurence Mealey. Tests will commence in late November. In addition the company announced plans to begin shipping ssDNA expression vector kits in late November. The kits will be provided to researchers for experimental purposes only and are governed by Materials Transfer Agreements between CYGS and the research facilities. A number of premiere universities and hospitals have requested such agreements to date. The agreements cover commercialization of all discoveries and developments resulting from the use of the company's technology. CYGS is also entertaining overtures from a number of major pharmaceutical companies. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion